NEW DELHI, Oct. 6, 2021 /PRNewswire/ — “Global EZH2 Inhibitor Market Opportunity, Sales & Clinical Trials Insight 2026” Report Highlights:
- Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026
- Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug
- Dosage, Price & Sales Analysis of Tazverik
- Tazverik Sales Opportunity > US$ 900 Million by 2026
- Tazverik Sales Forecast 2021 Till 2026
- EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication & Phase
- EZH2 Inhibitor in Clinical Trials: 7 Drugs
The advent of next generation sequencing has led to identification of multiple novel molecular alterations in cancer. Since the identification of DNA methylation and histone modification, it has now become evident that genes encoding epigenetic modifiers that locally and globally regulate gene expression play a crucial role in normal development and cancer progression. The field of cancer epigenetics has recently gained considerable interest due to role of epigenetic genes in progression of cancer as well as increasing ability to target these genes. In recent times, the histone methyltransferase enhancer of zeste homolog 2 (EZH2), which is enzymatic catalytic subunit of polycomb repressive complex 2 has emerged as a potential therapeutic target.
Tazemetostat (Tazverik) is an EZH2 inhibitor which has recently gained approval by US FDA. The drug Tazverik is developed by Epizyme Inc. and is indicated to treat patients 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Apart from this, the drug is also approved for the management of adult patients with relapsed or refractory follicular lymphoma, who have no satisfactory alternate options. Currently, the drug has been approved in US and Japan and has received orphan designation in Europe. Moreover, the clinical trials with the drug have demonstrated encouraging overall survival rate and positive response rate.
The accelerated approval of Tazemetostat in the management of cancer is thought to revolutionize the overall paradigm of cancer treatment. The global Tazemetostat market is valued around US$ XX Million in 2020 which is growing at a very high CAGR rates. This is mainly due to the robust sales of the drug in short span of time as well as high adoption rates in US. The exploitation of drug in other therapeutic conditions such as prostate cancer, ovarian cancers and other solid tumors will also aid in boosting the growth of market. Apart from this, it is expected that the drug will gain approval in other regions which will further propel the growth of market.
In coming years, the global market will witness increase in prevalence of cancer attributing to several factors including rising geriatric population, smoking, drinking, physical inactivity and poor diet. This will increase the demand of targeted therapies, thus driving the global EZH2 inhibitor drug market. In addition to Tazemetostat, several pharmaceutical companies have developed potential EZH2 inhibitors candidates including GSK126, CPI1205, SHR2554 and others which are present in clinical stage of development and are expected to gain approval during the forecast period.
As per our analysis, the global EZH2 inhibitor drug market will surpass US$ 1 Billion by 2026. The high growth rates in the market can be justified by the extensive research and development in this sector and the high adoption rates of approved drug. In addition to this, the rising initiative by government and the development of favorable reimbursement policies will also ensure the high uptake of the drug in the market. As per region, US is expected to dominate the global EZH2 inhibitor drug market due to high adoption rates, increasing research and development activities as well as increase in prevalence of cancer. Apart from this, Asia-Pacific is expected to grow with high CAGR due to presence of several untapped opportunities, cheap labor and rising awareness among the population.
SOURCE Kuick Research